Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing

Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing

Background Activating mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) are predictive biomarkers for response to EGFR–tyrosine kinase inhibitor (TKI) therapy in lung adenocarcinoma (LUAD). Here, we characterized the clinicopathologic features associated with EGFR mu...

Full description

Bibliographic Details
Main Authors:	Jeonghyo Lee, Yeon Bi Han, Hyun Jung Kwon, Song Kook Lee, Hyojin Kim, Jin-Haeng Chung
Format:	Article
Language:	English
Published:	Korean Society of Pathologists & the Korean Society for Cytopathology 2022-09-01
Series:	Journal of Pathology and Translational Medicine
Subjects:	lung adenocarcinoma epidermal growth factor receptor deep sequencing
Online Access:	http://www.jpatholtm.org/upload/pdf/jptm-2022-06-11.pdf

Similar Items

The prognostic implications of EGFR mutation and ALK rearrangement for the long‐term outcomes of patients with resected lung adenocarcinomas
by: Hyungjin Kim, et al.
Published: (2019-07-01)

Conventional transbronchial needle aspiration is promising for identifying EGFR mutations in lung adenocarcinoma
by: Li‐Han Hsu, et al.
Published: (2019-04-01)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
by: Wang Wen-Ping, et al.
Published: (2012-01-01)

Effect of thoracic radiotherapy dose on the prognosis of advanced lung adenocarcinoma harboring EGFR mutations
by: Hongyue Qin, et al.
Published: (2022-09-01)

Deep learning analysis to predict EGFR mutation status in lung adenocarcinoma manifesting as pure ground-glass opacity nodules on CT
by: Hyun Jung Yoon, et al.
Published: (2022-09-01)

Influence of the Timing of Leptomeningeal Metastasis on the Outcome of <i>EGFR</i>-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable <i>EGFR</i> Mutations in Cerebrospinal Fluid
by: Pei-Ya Liao, et al.
Published: (2022-06-01)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
by: Ping-Chih Hsu, et al.
Published: (2020-10-01)

Optimal 18F-FDG PET/CT radiomics model development for predicting EGFR mutation status and prognosis in lung adenocarcinoma: a multicentric study
by: Yan Zuo, et al.
Published: (2023-05-01)

Emerging EGFR-Mutated Subclones in a Patient With Metastatic ALK-Rearranged Lung Adenocarcinoma Treated With ALK-Targeted Therapy: A Case Report
by: Jackson Ka Chun Leung, M.B.B.S., et al.
Published: (2023-07-01)

Identification of Targetable Liabilities in the Dynamic Metabolic Profile of <i>EGFR</i>-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance
by: Anastasios Gkountakos, et al.
Published: (2022-01-01)

Thyroid transcription factor 1 (TTF‐1) negativity as a predictor of unfavorable response to EGFR‐TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations
by: Xiaosheng Ding, et al.
Published: (2023-10-01)

A Machine Learning-Based Predictive Model of Epidermal Growth Factor Mutations in Lung Adenocarcinomas
by: Ruimin He, et al.
Published: (2022-09-01)

The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center
by: Yicheng Xiong, et al.
Published: (2023-01-01)

The predictive value of [18F]FDG PET/CT radiomics combined with clinical features for EGFR mutation status in different clinical staging of lung adenocarcinoma
by: Jianxiong Gao, et al.
Published: (2023-04-01)

Transfer learning–based PET/CT three-dimensional convolutional neural network fusion of image and clinical information for prediction of EGFR mutation in lung adenocarcinoma
by: Xiaonan Shao, et al.
Published: (2024-03-01)

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors
by: Ping-Chih Hsu, et al.
Published: (2023-10-01)

Associations of <i>TIMP-3</i> Genetic Polymorphisms with <i>EGFR</i> Statuses and Cancer Clinicopathologic Development in Lung Adenocarcinoma Patients
by: Jer-Hwa Chang, et al.
Published: (2020-10-01)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
by: Chieh-Lung Chen, et al.
Published: (2023-09-01)

Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes
by: Chia-Yu Kuo, et al.
Published: (2022-12-01)

Prognostic significance of integrating total metabolic tumor volume and EGFR mutation status in patients with lung adenocarcinoma
by: Maoqing Jiang, et al.
Published: (2024-01-01)

MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma
by: Lu Bai, et al.
Published: (2023-01-01)

Potential Impacts of <i>Interleukin-17A</i> Promoter Polymorphisms on the <i>EGFR</i> Mutation Status and Progression of Non-Small Cell Lung Cancer in Taiwan
by: Kai-Ling Lee, et al.
Published: (2021-03-01)

Gene Expression Profiles of Multiple Synchronous Lesions in Lung Adenocarcinoma
by: Jisun Lim, et al.
Published: (2021-12-01)

Osteosarcomatous Differentiation in Rebiopsy Specimens of Pulmonary Adenocarcinoma with EGFR-TKI Resistance
by: Hyein Ahn, et al.
Published: (2018-03-01)

The urine as a diagnostic key for a homozygous EGFR mutation
by: Mafalda Casinhas Santos, et al.
Published: (2022-03-01)

High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
by: Ji-Youn Sung, et al.
Published: (2022-08-01)

Efficacy of Chemotherapy after EGFR-TKIs Resistance in 191 Patients with Unknow EGFR Gene Mutation in Advanced Lung Adenocarcinoma
by: Ping HE, et al.
Published: (2013-10-01)

Testing EGFR with Idylla on Cytological Specimens of Lung Cancer: A Review
by: Alessandro Caputo, et al.
Published: (2021-05-01)

Targeted Next-Generation Sequencing Analysis Predicts the Recurrence in Resected Lung Adenocarcinoma Harboring <i>EGFR</i> Mutations
by: In Ae Kim, et al.
Published: (2021-07-01)

Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing
by: Hainan Yang, et al.
Published: (2022-05-01)

An Explainable Radiogenomic Framework to Predict Mutational Status of KRAS and EGFR in Lung Adenocarcinoma Patients
by: Berardino Prencipe, et al.
Published: (2023-06-01)

Comparison of next‐generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations
by: Shuji Murakami, et al.
Published: (2022-11-01)

Gallbladder Adenocarcinoma, Potential Target for Anti-Her-2 Therapy
by: Ghazi Zafar, et al.
Published: (2020-08-01)

Ampullary Adenocarcinoma: A Review of the Mutational Landscape and Implications for Treatment
by: Vasileios Tsagkalidis, et al.
Published: (2023-12-01)

Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study
by: Jianghua Ding, et al.
Published: (2023-06-01)

Correlation Analysis of Ki67 Expression and EGFR Mutation on the Risk of Recurrence and Metastasis in Postoperative Patients with Stage I Lung Adenocarcinoma
by: Lili XU, et al.
Published: (2022-12-01)

Association of Carbonic Anhydrase 9 Polymorphism and the Epithelial Growth Factor Receptor Mutations in Lung Adenocarcinoma Patients
by: Ya-Yen Yu, et al.
Published: (2020-04-01)

De Novo T790M Mutation in an L858R Epidermal Growth Factor Receptor Mutant-Associated Lung Adenocarcinoma
by: Takumi Fujiwara, et al.
Published: (2020-10-01)

Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?
by: Sviatoslav Chekhun, et al.
Published: (2023-12-01)

Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug–Disease Mechanistic Model Approach in EGFR-Mutated Lung Adenocarcinoma
by: Hippolyte Darré, et al.
Published: (2024-03-01)